Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-28
2011-06-28
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07968300
ABSTRACT:
The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.
REFERENCES:
patent: 5811097 (1998-09-01), Allison et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 6051227 (2000-04-01), Allison et al.
patent: 6207156 (2001-03-01), Kuchroo et al.
patent: 6228361 (2001-05-01), Posner
patent: 7229628 (2007-06-01), Allison et al.
patent: 2003/0049696 (2003-03-01), Norment et al.
patent: WO 2007/117602 (2005-02-01), None
patent: WO 2005/012495 (2007-10-01), None
Alegre et al., Nat. Rev. Immunol., 2001, 1: 220-228.
Birebent, B, et al, 2004, “Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression,” Eur. J. Immunol., 34:3485-96.
Burstein, S and Knapp, R, 1977, “Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates,” J. Med. Chem., 20:950-2.
Chikuma, S and Bluestone, JA, 2002, “CTLA-4: acting at the synapse,” Mol. Interv., 2:205-8.
Chin, LT, et al, 2001, “Establishment and evaluation of mouse-human heteromyeloma cell lines obtained by electrofusion for immortalizing human immunoglobulins,” J. Biom.
Chin, LT, et al, 2007, Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152.
Dannull, J, et al, 2005, “Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells,” J. Clin. Invest., 115:3623-33.
Davis, DM and Dustin, ML, 2004, “What is the importance of the immunological synapse?” Trends Immunol., 25:323-7.
Duenas M, et al, 1996, “In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display,” Immunology, 89:1.
Dustin, ML, 2002, “The immunological synapse,” Arthritis Res., 4 Suppl 3: S119-25.
Egen, JG and Allison, JP, 2002, “Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength,” Immunity, 16:23-35.
Egen, JG, et al, 2002, “CTLA-4: new insights into its biological function and use in tumor immunotherapy,” Nat. Immunol., 3:611-8.
Gough, SC, et al, 2005, “CTLA4 gene polymorphism and autoimmunity,” Immunol. Rev., 204:102-15.
Grakoui, A, et al, 1999, “The immunological synapse: a molecular machine controlling T cell activation,” Science, 285:221-7.
Hori, S, et al, 2003, “Control of regulatory T cell development by the transcription factor Foxp3,” Science, 299:1057-61.
Krummel, MF and Allison, JP, 1996,“CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells,” J. Exp. Med., 183:2533-4.
Linsley, PS, et al, 1991, “CTLA-4 is a second receptor for the B cell activation antigen B7,” J. Exp. Med., 174:561-9.
Linsley, PS, et al, 1992, “Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes,” J. Exp. Med., 176:1595-604.
Lopes, JE, et al, 2006, “Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor,” J. Immunol., 177, 3133-42.
Magistrelli, G, et al, 1999, “A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells,” Eur. J. Immunol., 29:3596-602.
Nistico, L, et al, 1996, “The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry,” Hum. Mol. Genet., 5: pp. 1075-1080.
Oaks, MK and Hallett, KM, 2000, “A soluble form of CTLA-4 in patients with autoimmune thyroid disease,” J. Immunol., 164:5015-8.
Oaks, MK, et al, 2000, “A native soluble form of CTLA-4,” Cell. Immunol., 201:144-53.
Peach, RJ, et al, 1994, “Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1,” J. Exp. Med., 180:20.
Pioli, C, et al, 2000, “Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor” J. Immunol., 165:5530-6.
Prud'homme, GJ, 2004, “Altering immune tolerance therapeutically: the power of negative thinking,” J. Leukoc. Biol., 75:586-99.
Qi, SY, et al, 2001, “Synaptic pattern formation during cellular recognition,” Proc. Natl. Acad. Sci. USA, 98:6548-53.
Rao, A, et al, 2007, “Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning,” Blood, 109:383-5.
Read, S, et al, 2006, “Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo,” J. Immunol., 177:4376-83.
Sakaguchi, S, 2005, “Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self,” Nat. Immunol., 6:345-52.
Sato, S, et al, 2004, “Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis,” Rheumatology, 43:1261-6.
Schwartz, JC, et al, 2001, “Structural basis for co-stimulation by the human CTLA-4/B7-2 complex,” Nature, 410:604-8.
Sharpe, AH and Freeman, GJ, 2002, “The B7-CD28 superfamily” Nat. Rev. Immunol., 2:116-26.
Stamper, CC, et al, 2001, “Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses,” Nature, 410:608-11.
Steiner, K, et al, 1999, “Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection,” Clin. Exp. Immunol., 115:451-7.
Takahashi, T, et al, 2000, Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antige.
Tivol, EA, et al, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of C.
von Boehmer, H, 2005, “Mechanisms of suppression by suppressor T cells,” Nat. Immunol., 6:338-44.
Wang, S and Chen, L, 2004, “T lymphocyte co-signaling pathways of the B7-CD28 family,” Cell. Mol. Immunol., 1:37-42.
Ward, FJ and Barker, RN, 2007, “Soluble CTLA-4 responses—a novel mechanism for regulatory T cell suppression?” Immunology, 120, Suppl:9 (meeting abstract).
Wildin, RS and Freitas, A, 2005, “IPEX and FOXP3: clinical and research perspectives,” J. Autoimmun., 25 Suppl:56-62.
Wong, CK, et al, 2005, “Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus,” Rheumatology.
[0050] Wong, CK, et al, 2005, “Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma,” Clin. Ex.
Wu, Y, et al, 2006, “FOXP3 controls regulatory T cell function through cooperation with NFAT,” Cell, 126:375-87.
Xystrakis, E, et al, 2004, “Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation,” Blood, 104:3294-301.
Chin Li-Te
Hsu Shu-Ching
Chow Ming
Ouspenski Ilia
Sinorica LLC
LandOfFree
Method of isolating regulatory T cells from human samples does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of isolating regulatory T cells from human samples, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of isolating regulatory T cells from human samples will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686531